> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Cupric Sulfate Not Withdrawn Due to Safety/Efficacy
- URL: https://www.fdaweb.com/cupric-sulfate-not-withdrawn-due-to-safety-efficacy/
- Published: 2022-04-28T12:00:00.000Z
- Updated: 2026-09-14T17:42:38.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5151698

*Federal Register* notice: FDA has determined that Abraxis Pharmaceutical’s cupric sulfate injection was not withdrawn from sale for reasons of safety or effectiveness. The determination will allow FDA to approve ANDAs that reference the product if all other legal and regulatory requirements are met. The product is indicated to prevent and treat copper deficiency. To view the notice, click [here](https://public-inspection.federalregister.gov/2022-09238.pdf?ref=fdaweb.com).